OINDPnews

Nocion initiates Phase 2b trial of NOC-110 taplucainium DPI for the treatment of chronic cough

Nocion Therapeutics has announced the initiation of the Phase 2b ASPIRE clinical trial of its NOC-110 inhaled dry powder taplucainium (formerly NTX-1175) in patients with chronic cough. Earlier this year, the company said that it had raised $62 million to conduct the trial, which is expected to … [Read More...] about Nocion initiates Phase 2b trial of NOC-110 taplucainium DPI for the treatment of chronic cough

NurExone’s ExoPTEN intranasal exosome therapy for spinal cord injuries get orphan designation from the EMA

NurExone Biologic announced that the EMA has granted orphan medicinal product designation to NurExone's ExoPTEN intranasal exosome therapy, which the company is developing for the treatment of spinal cord injury. In 2023, the FDA granted orphan drug designation to ExoPTEN, and the company held a … [Read More...] about NurExone’s ExoPTEN intranasal exosome therapy for spinal cord injuries get orphan designation from the EMA

AlveoGene’s AVG-002 inhaled gene therapy gets rare pediatric disease designation for SP-B deficiency

UK-based start-up AlveoGene announced that its AVG-002 nebulized gene therapy for neonatal surfactant protein B (SP-B) deficiency has received a rare pediatric disease designation from the FDA. The company says that it will advance AVG-002 into clinical development and could submit a marketing … [Read More...] about AlveoGene’s AVG-002 inhaled gene therapy gets rare pediatric disease designation for SP-B deficiency

Pulmatrix agrees to merge with Cullgen and will divest inhalation assets

Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including PUR1800 inhaled dry powder narrow spectrum kinase … [Read More...] about Pulmatrix agrees to merge with Cullgen and will divest inhalation assets

ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world

Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the US, Australia, New Zealand, Japan, and China. In addition … [Read More...] about ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world

More news . . .

DDL 2024 to celebrate 35 years as a leading OINDP conference

A Q&A with Copley’s Clair Brooks on alternative BE approaches in new FDA guidance

Human Factors (HF) Considerations for Generic Inhalers Using Off-the-shelf Devices

Latest news

Nocion initiates Phase 2b trial of NOC-110 taplucainium DPI for the treatment of chronic cough

NurExone’s ExoPTEN intranasal exosome therapy for spinal cord injuries get orphan designation from the EMA

AlveoGene’s AVG-002 inhaled gene therapy gets rare pediatric disease designation for SP-B deficiency

Pulmatrix agrees to merge with Cullgen and will divest inhalation assets

ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world

Other recent news